Federal Policy
KFF Analysis Finds TrumpRx Prices Below OECD Average for 17 of 32 Brand-Name Drugs
A Peterson-KFF Health System Tracker analysis compared prices for 32 brand-name drugs on TrumpRx.gov—a federal portal launched in February 2026 offering medications from manufacturers that signed voluntary pricing agreements with the White House—to publicly listed prices in 11 wealthy OECD countries. TrumpRx prices were lower than the OECD peer average for 17 drugs and higher for 15; TrumpRx had the lowest price for 5 drugs and the highest for 13. The analysis does not assess whether these negotiated prices affect Medicaid or Medicare reimbursement, whether domestic prices outside TrumpRx have changed, or how the retail prices compare to net costs after rebates in Medicaid or other public programs.
Why it mattersIf TrumpRx pricing influences manufacturer list prices or federal upper limits, state Medicaid agencies and health plans could see changes to reimbursement baselines, rebate calculations, and pharmacy cost structures—though the analysis provides no evidence yet of programmatic spillover.
Also covered by:kff.org